Company: MIRM
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001759425-25-000041
Chunk: 337

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 337
---
ulative translation adjustments622 (471)760 (2,128)Comprehensive loss$(5,251)$(25,102)$(19,813)$(52,038)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

Mirum Pharmaceuticals, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands, except share amounts)

 Common StockAdditionalPaid-InCapitalAccumulatedDeficitAccumulatedOtherComprehensive Income (Loss) TotalStockholders’Equity  SharesAmountBalance as of December 31, 2024 48,338,096$5 $870,189 $(644,181)$(373)$225,640 Issuance of common stock in connection with equity award plans1,112,939— 6,359 — — 6,359 Conversion of convertible notes, net188— 6 — — 6 Stock-based compensation—— 15,813 — — 15,813 Net loss—— — (14,677)— (14,677)Other comprehensive income—— — — 115 115 Balance as of March 31, 202549,451,2235 892,367 (658,858)(258)233,256 Issuance of common stock in connection with equity award plans547,323— 6,575 — — 6,575 Issuance of common stock in connection with employee stock purchase plan59,752— 2,113 — — 2,113 Conversion of convertible notes, net94— 3 — — 3 Stock-based compensation—— 18,462 — — 18,462 Net loss—— — (5,861)— (5,861)Other comprehensive income—— — — 610 610 Balance as of June 30, 202550,058,392$5 $919,520 $(664,719)$352 $255,158 

 Common StockAdditionalPaid-InCapitalAccumulatedDeficit AccumulatedOtherComprehensiveIncome (Loss)TotalStockholders’Equity  SharesAmountBalance as of December 31, 2023 46,723,143$5 $803,260 $(556,239)$1,644 $248,670 Issuance of common